EFFICACY OF IMMUNECOV ™ IN PATIENTS WITH COVID-19
DOI:
https://doi.org/10.11603/1811-2471.2022.v.i1.13002Keywords:
SARS-CoV-2019, pneumonia, inflammatory markersAbstract
SUMMARY. COVID-19 treatment is currently a major unresolved issue. The study of the properties of drugs that could be used in the treatment of this disease is an urgent task. Theoretically effective agents in the treatment of COVID-19 could be substances that improve the immune system. One such remedy is ImmuneCOV. This preparation is a combination of natural complex components and plant extracts that grow in Israel.
The aim – to investigate the therapeutic properties of the drug ImmuneCOV ™ in patients with moderate COVID-19.
Material and Methods. The study was randomized and controlled. A total of 58 patients with moderate COVID-19 who required oxygen support and had no comorbidities were studied. Patients were divided into two groups: those who received the drug and standard treatment (n=30), and those who received only standard treatment (n=28). Results. Patients with ImmuneCOV ™ on day 14 had significantly higher values of SpO2 (95.3±2.27) compared with the second group (93.38±2.14; p<0.05), significantly lower values ferritin (130.9±6,23 and 196.55±12.81, respectively; p<0.05), significantly lower values of C-reactive protein (7.7±0.72 and 24.05±3.22; p<0.05).
Conclusions. The use of ImmuneCOV ™ in patients with moderate COVID-19 leads to a significant increase in SpO2 (p<0.05), a decrease in serum ferritin (p<0.05) and C-reactive protein (p<0.05). The ImmuneCOV ™ can be successfully used to treat moderate COVID-19.
References
Coronavirus Disease 2019 (COVID-19) Treatment Guidelines Get the latest public health information from CDC: https://www.coronavirus.gov
(2021). Instruktsia do preparatu ImmuneCOV™ [Instructions for the drug]. LIBI PHARM. Kyiv [in Ukrainian].
Ruscitti, P., & Giacomelli, R. (2020). Ferritin and severe COVID-19, from clinical observations to pathogenic implications and therapeutic perspectives. Isr. Med. Assoc. J., 8(22), 450-452.
McGonagle, D., Sharif, K., O'Regan, A., & Bridgewood, C. (2020). The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun. Rev., 19(6), 102537. DOI: 10.1016/j.autrev.2020.102537.
Williams, D.K., & Muddiman, J. (2009). Absolute quantification of c-reactive protein in human plasma derived from patients with epithelial ovarian cancer utilizing protein cleavage isotope dilution mass spectrometry. J. Proteome. Res., 8(2), 1085-1090. DOI: 10.1021/pr800922p.
Gosselin, R.C., Owings, J.T., & Utter, G.H. (2000). A new method for measuring D-dimer using immunoturbidometry: a study of 255 patients with suspected pulmonary embolism and deep vein thrombosis. Blood. Coagul. Fibrinolysis, 11(8), 715-721. DOI: 10.1097/00001721-200012000-00004.
Song, J., Park, D.W., & Moon, S. (2019). Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the Sepsis-3 definitions. BMC Infect. Dis., 19, 968. DOI: 10.1097/00001721-200012000-00004.
Kieliszek, M., & Lipinski, B. (2020). Selenium supplementation in the prevention of coronavirus infections (COVID-19). Med. Hypotheses., 143, 109878. DOI: 10.1016/j.mehy.2020.109878.
Zhang, J., Taylor, E.W., & Bennett, K. (2020). Association between regional selenium status and reported outcome of COVID-19 cases in China. Am. J. Clin. Nutr., 111(6), 1297-1299. DOI: 10.1093/ajcn/nqaa095.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Achievements of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
